Natco Pharma Promoters and Promoter Group Acquire 22.11 Lakh Shares Through Rights Issue
The disclosures show that 11 promoter and promoter group entities acquired shares in Natco Pharma Limited through its Rights Issue. The largest acquisitions were made by Time Cap Pharma Labs Private Limited, which acquired 9,33,333 shares, and Venkaiah Chowdary Nannapaneni, who acquired 5,86,666 shares.
Other acquisitions included 2,55,387 shares by Neelima Sita Nannapaneni, 58,666 shares by Rajeev Nannapaneni, 61,333 shares by VS Swathi Kantamani and 4,761 shares by KR Kumar. Natsoft Information Systems Private Limited acquired 2,40,000 shares.
The remaining shares were acquired by Vistra ITCL India Limited A/C Neelima Nannapaneni Trust, Vistra ITCL India Limited A/C VCN Family Trust, Natco Aqua Limited and SAU Family Trust.
Key Promoter Shareholding Changes
Time Cap Pharma Labs Private Limited increased its holding from 1,71,75,420 shares (8.76%) to 1,81,08,753 shares (9.23%) after acquiring 9,33,333 shares.
Venkaiah Chowdary Nannapaneni increased his holding from 2,80,45,905 shares (14.30%) to 2,86,32,571 shares (14.60%) after acquiring 5,86,666 shares.
Natco Pharma Rights Issue Acquisition Highlights
| Particulars | Details |
| Total shares acquired | 22,11,776 |
| Issue price | Rs. 750 per share |
| Total acquisition value | About Rs. 165.88 crore |
| Mode of acquisition | Rights Issue |
| Date of acquisition | October 26, 2026 |
| Acquiring promoter/promoter group entities | 11 |
| Post-allotment equity share capital | 19,61,67,952 shares of Rs. 2 each |
What to Watch Next
- Investors can track further disclosures on promoter and promoter group shareholding following the Rights Issue, along with any subsequent changes in their holdings.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Jio Financial Services Allots 25 Crore Shares to Promoter Group Entities
Jio Financial Services Limited has allotted 25 crore equity shares to two promoter group entities following the conversion of preferential warrants. The allotment was made at Rs.316.50 per share, including a face value of Rs.10 and a premium of Rs.306.50 per share.
Ginni Filaments: SBICAP Trustee Releases Encumbrance on 26.48 Lakh Shares
SBICAP Trustee Company Limited has disclosed the release of encumbrance on 26,48,300 equity shares of Ginni Filaments Limited under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The released shares represent 3.09% of the total voting share capital of Ginni Filaments. Following the transaction dated October 29, 2026, SBICAP Trustee's encumbered shareholding declined from 1,04,08,300 equity shares (12.15%) to 77,60,000 equity shares (9.06%). The transaction was executed by SBICAP Trustee Company Limited in its capacity as a Security Trustee. The entity does not belong to the promoter or promoter group of Ginni Filaments.
Sun Pharma Gets US FDA Approval for ILUMYA to Treat Psoriatic Arthritis
Sun Pharmaceutical Industries has received US FDA approval for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis (PsA). The approval expands the drug's use beyond plaque psoriasis and gives the company access to another segment of the US immunology market.